Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
NCT ID: NCT06424964
Last Updated: 2025-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2025-01-13
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV
Secondary outcomes
• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries
NCT04399551
Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units".
NCT06159894
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805
Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine
NCT06403865
A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
NCT06518408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belgian Research on AIDS and HIV Consortium
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rakan Nasreddine
Head of Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stéphane De Wit, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
Belgian Research on AIDS & HIV Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint-Pierre University Hospital
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stéphane De Wit
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024/1-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.